Rentschler Biopharma Appoints Dr. Veit Bergendahl as COO

Rentschler Biopharma SE has announced the appointment of Dr. Veit Bergendahl as Chief Operating Officer and executive board member. He will begin on April 1, 2026, succeeding Christiane Bardroff. Dr. Bergendahl will manage process development, cGMP manufacturing, engineering, and production automation.

With over two decades of experience in biopharmaceutical development and manufacturing, Dr. Bergendahl has held various roles across Europe and the US. His expertise encompasses the biopharmaceutical value chain, from development to production. He plans to drive sustainable growth and strengthen Rentschler’s operations.

Previously with Boehringer Ingelheim, he contributed significantly to the Biologicals Development Center in Biberach, Germany. Dr. Bergendahl holds a degree in biochemistry and a doctorate in biology from Philipps University, Marburg.